Nanoparticle-loaded microbubbles for treatment of lung cancer.

Autor: Snipstad S; Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway; Department of Physics, Norwegian University of Science and Technology, Trondheim, Norway; Cancer Clinic, St. Olavs Hospital, Trondheim, Norway. Electronic address: sofie.snipstad@ntnu.no., Sulheim E; Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway; Institute for Research in Biomedicine, Bellinzona, Switzerland., Åslund AKO; Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway., Hyldbakk A; Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway; Department of Physics, Norwegian University of Science and Technology, Trondheim, Norway., Wågbø AM; Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway., Klinkenberg G; Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway., Mørch Y; Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway; NaDeNo Nanoscience AS, Trondheim, Norway.
Jazyk: angličtina
Zdroj: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2024 Aug 01; Vol. 199, pp. 106804. Date of Electronic Publication: 2024 May 17.
DOI: 10.1016/j.ejps.2024.106804
Abstrakt: Lung cancer is one of the most common cancers and a leading cause of death, with poor prognosis and high unmet clinical need. Chemotherapy is a common part of the treatment, either alone or in combination with other treatment modalities, but with limited efficacy and severe side effects. Encapsulation of drugs into nanoparticles can enable a more targeted delivery with reduced off-target toxicity. Delivery to the lungs is however often insufficient due to various biological barriers in the body and in the tumor microenvironment. Here we demonstrate that by incorporating drug-loaded nanoparticles into air-filled microbubbles, a more effective targeting to the lungs can be achieved. Fluorescence imaging and mass spectrometry revealed that the microbubbles could significantly improve accumulation of drug in the lungs of mice, compared to injecting either the free drug by itself or only the drug-loaded nanoparticles. Therapeutic efficacy was verified in a preclinical mouse model with non-small cell lung cancer, monitoring tumor growth by luminescence.
Competing Interests: Conflict of interest Einar Sulheim and Yrr Mørch are co-inventors of a patent describing the nanoparticle-loaded microbubble technology (US 16/643682 (pending), EP 18768825.4 (granted)). Yrr Mørch is from August 2022 CTO and Co-founder of the SINTEF Spin-off NaDeNo Nanoscience AS commercializing PEBCA nanoparticles for cancer treatment. Sofie Snipstad is from April 2023 employed part time as a scientist in NaDeNo Nanoscience AS. All other authors have no competing interests.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: